Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1127-1134

  Higgins, Deborah L ^a   Chang, Ray ^a   Debabov, Dmitri V ^a   Leung, Joey ^a   Wu, Terry ^a   Krause, Kevin M ^a   Sandvik, Erik ^a   Hubbard, Jeffrey M ^a   Kaniga, Koné ^a   Schmidt Jr , Donald E ^a   Gao, Qiufeng ^a   Cass, Robert T ^a   Karr, Dane E ^a   Benton, Bret M ^a   Humphrey, Patrick P ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; GLYCOPEPTIDE; HEXAPEPTIDE; LIPID; LIPOGLYCOPEPTIDE; N,N' DIACETYLLYSINE DEXTRO ALANYL DEXTRO ALANINE; POTASSIUM ION; TELAVANCIN; THRX 881620; TRIPEPTIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CELL FRACTIONATION; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE POTENTIAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GRAM POSITIVE BACTERIUM; MEMBRANE BINDING; MEMBRANE DAMAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

AMINOGLYCOSIDES; CELL MEMBRANE; CELL WALL; METHICILLIN RESISTANCE; PEPTIDOGLYCAN; STAPHYLOCOCCUS AUREUS;

EID: 20044363986     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1127-1134.2005     Document Type: Article

References (57)

1. Allen, N. E., J. N. Hobbs, Jr., and T. I. Nicas. 1996. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semi-synthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 40:2356-2362.
2. Allen, N. E., D. L. LeTourneau, and J. N. Hobbs, Jr. 1997. Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob. Agents Chemother. 41:66-71.
3. Allen, N. E., D. L. LeTourneau, and J. N. Hobbs, Jr. 1997. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J. Antibiot. (Tokyo) 50:677-684.
4. Allen, N. E., D. L. LeTourneau, J. N. Hobbs, Jr., and R. C. Thompson. 2002. Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies. Antimicrob. Agents Chemother. 46:2344-2348.
5. Allen, N. E., and T. I. Nicas. 2003. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26:511-532.
6. Avila, L. Z., Y. H. Chu, E. C. Blossey, and G. M. Whitesides. 1993. Use of affinity capillary electrophoresis to determine kinetic and equilibrium constants for binding of arylsulfonamides to bovine carbonic anhydrase. J. Med. Chem. 36:126-133.
7. Baizman, E. R., A. A. Branstrom, C. B. Longley, N. Allanson, M. J. Sofia, D. Gange, and R. C. Goldman. 2000. Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. Microbiology 146:3129-3140.
8. Barna, J. C., and D. H. Williams. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38:339-357.
9. Beauregard, D. A., D. H. Williams, M. N. Gwynn, and D. J. Knowles. 1995. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39:781-785.
10. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37:911-917.
11. Branstrom, A. A., S. Midha, and R. C. Goldman. 2000. In situ assay for identifying inhibitors of bacterial transglycosylase. FEMS Microbiol. Lett. 191:187-190.
12. Breukink, E., I. Wiedemann, C. van Kraay, O. P. Kuipers, H. Sahl, and B. de Kruijff. 1999. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286:2361-2364.
13. Brumfitt, W., M. R. Salton, and J. M. Hamilton-Miller. 2002. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50:731-734.
14. Bunthof, C. J., S. van Schalkwijk, W. Meijer, T. Abee, and J. Hugenholtz. 2001. Fluorescent method for monitoring cheese starter permeabilization and lysis. Appl. Environ. Microbiol. 67:4264-4271.
15. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morbid. Mortal. Wkly. Rep. 51:565-567.
16. Chen, L., D. Walker, B. Sun, Y. Hu, S. Walker, and D. Kahne. 2003. Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc. Natl. Acad. Sci. USA 100:5658-5663.
17. Chu, Y.-H., and G. M. Whitesides. 1992. Affinity capillary electrophoresis can simultaneously measure binding constants of multiple peptides to vancomycin. J. Org. Chem. 57:3524-3525.
18. Colton, I. J., J. D. Carbeck, J. Rao, and G. M. Whitesides. 1998. Affinity capillary electrophoresis: a physical-organic tool for studying interactions in biomolecular recognition. Electrophoresis 19:367-382.
19. Cooper, M. A., and D. H. Williams. 1999. Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium. Chem. Biol. 6:891-899.
20. Cooper, R. D., N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. L. Mullen, T. F. Butler, M. J. Rodriguez, B. E. Huff, and R. C. Thompson. 1996. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. (Tokyo) 49:575-581.
21. Cristofaro, M. F., D. A. Beauregard, H. Yan, N. J. Osborn, and D. H. Williams. 1995. Cooperativity between non-polar and ionic forces in the binding of bacterial cell wall analogues by vancomycin in aqueous solution. J. Antibiot. (Tokyo) 48:805-810.
22. Ganzle, M. G., and R. F. Vogel. 2003. Studies on the mode of action of reutericyclin. Appl. Environ. Microbiol. 69:1305-1307.
23. Ge, M., Z. Chen, H. R. Onishi, J. Kohler, L. L. Silver, R. Kerns, S. Fukuzawa, C. Thompson, and D. Kahne. 1999. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284:507-511.
24. Goldman, R. C., E. R. Baizman, C. B. Longley, and A. A. Branstrom. 2000. Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding. FEMS Microbiol. Lett. 183:209-214.
25. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152.
26. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J. P. Shaw, G. Obedencio, and J. K. Judice. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050.
27. Jorgensen, T. J., and P. Roepstorff. 1998. Direct determination of solution binding constants for noncovalent complexes between bacterial cell wall peptide analogues and vancomycin group antibiotics by electrospray ionization mass spectrometry. Anal. Chem. 70:4427-4432.
28. Judice, J. K., and J. L. Pace. 2003. Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13:4165-4168.
29. Jung, D., A. Rozek, M. Okon, and R. E. Hancock. 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11:949-957.
30. Kerns, R., S. D. Dong, S. Fukuzawa, J. Carbeck, J. Kohler, L. Silver, and D. Kahne. 2002. The role of hydrophobic substituents in the biological activity of glycopeptide antibiotics. J. Amer. Chem. Soc. 122:12608-12609.
31. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavanein (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
32. Kohlrausch, U., and J. V. Holtje. 1991. One-step purification procedure for UDP-N-acetylmuramyl-peptide murein precursors from Bacillus cereus. FEMS Microbiol. Lett. 62:253-257.
33. Leadbetter, M. R., S. M. Adams, B. Bazzini, P. R. Fatheree, D. E. Karr, K. M. Krause, B. M. Lam, M. S. Linsell, M. B. Nodwell, J. L. Pace, K. Quast, J. P. Shaw, E. Soriano, S. G. Trapp, J. D. Villena, T. X. Wu, B. G. Christensen, and J. K. Judice. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavanein (TD-6424). J. Antibiot. (Tokyo). 57:326-336.
34. Mackay, J. P., U. Gerhard, D. A. Beauregard, D. H. Williams, M. S. Westwell, and M. S. Searle. 1994. Glycopeptide antibiotic activity and the possible role of dimerization: a model for biological signaling. J. Am. Chem. Soc. 116:4581-4590.
35. Malabarba, A., and R. Ciabatti. 2001. Glycopeptide derivatives. Curr. Med. Chem. 8:1759-1773.
36. Malabarba, A., T. I. Nicas, and R. C. Thompson. 1997. Structural modifications of glycopeptide antibiotics. Med. Res. Rev. 17:69-137.
37. Nagarajan, R., A. A. Schabel, J. L. Occolowitz, F. T. Counter, J. L. Ott, and A. M. Felty-Duckworth. 1989. Synthesis and antibacterial evaluation of N-alkyl vancomycins. J. Antibiot. (Tokyo). 42:63-72.
38. National Committee for Clinical Laboratory Standards. 2002. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 5th ed., M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
39. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. E. Stratford, and R. D. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
40. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
41. Nieto, M., and H. R. Perkins. 1971. Physicochemical properties of vancomycin and iodovancomycin and their complexes with diacetyl-L-lysyl-D- alanyl-D-alanine. Biochem. J. 123:773-787.
42. Nieto, M., H. R. Perkins, and P. E. Reynolds. 1972. Reversal by a specific peptide (diacetyl-alpha gamma-L-diaminobutyryl-D-alanyl-D-alanine) of vancomycin inhibition in intact bacteria and cell-free preparations. Biochem. J. 126:139-149.
43. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, J. K. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
44. Popieniek, P. H., and R. F. Pratt. 1987. A fluorescent ligand for binding studies with glycopeptide antibiotics of the vancomycin class. Anal. Biochem. 165:108-113.
45. Printsevskaya, S. S., A. Y. Pavlov, E. N. Olsufyeva, E. P. Mirchink, E. B. Isakova, M. I. Reznikova, R. C. Goldman, A. A. Branstrom, E. R. Baizman, C. B. Longley, F. Sztaricskai, G. Batta, and M. N. Preobrazhenskaya. 2002 Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria. J. Med. Chem. 45:1340-1347.
46. Reynolds, P. E. 1989. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8:943-950.
47. Sampson, B. A., R. Misra, and S. A. Benson. 1989. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122:491-501.
48. Schwalbe, R. S., A. C. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419.
49. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
50. Sinha, R. R., P. Yang, S. Kodali, Y. Xiong, R. M. Kim, P. R. Griffin, H. R. Onishi, J. Kohler, L. L. Silver, and K. Chapman. 2001. Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis. Chem. Biol. 8:1095-1106.
51. Stratton, C. W., C. Liu, H. B. Ratner, and L. S. Weeks. 1987. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofioxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. 31:1014-1016.
52. Vollmerhaus, P. J., E. Breukink, and A. J. Heck. 2003. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics. Chemistry 9:1556-1565.
53. Walsh, C. T., S. L. Fisher, I. S. Park, M. Prahalad, and Z. Wu. 1996. Bacterial resistance to vaneomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3:21-28.
54. Williams, D. H., and J. P. Waltho. 1988. Molecular basis of the activity of antibiotics of the vancomycin group. Biochem. Pharmacol. 37:133-141.
55. Wu, M., E. Maier, R. Benz, and R. E. Hancock. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38:7235-7242.
56. Xiong, Y. Q., M. R. Yeaman, and A. S. Bayer. 1999. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob. Agents Chemother. 43:1111-1117.
57. Yeaman, M. R., A. S. Bayer, S. P. Koo, W. Foss, and P. M. Sullam. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Investig. 101:178-187.